Vuslat Yilmaz

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4698130/publications.pdf

Version: 2024-02-01

63 papers	1,101 citations	471509 17 h-index	434195 31 g-index
64 all docs	64 docs citations	64 times ranked	1728 citing authors

#	Article	IF	Citations
1	Elevated sTREM2 and NFL levels in patients with sepsis associated encephalopathy. International Journal of Neuroscience, 2023, 133, 327-333.	1.6	12
2	CXCL13 Levels Indicate Treatment Responsiveness to Fingolimod in MS Patients. European Neurology, 2022, 85, 69-71.	1.4	3
3	Classical complement pathway factor alterations in narcolepsy. Acta Neuropsychiatrica, 2022, 34, 212-219.	2.1	2
4	Fingolimod impairs inactivated vaccine (CoronaVac)-induced antibody response to SARS-CoV-2 spike protein in persons with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 58, 103524.	2.0	8
5	IgG4 Autoantibodies in Organ-Specific Autoimmunopathies: Reviewing Class Switching, Antibody-Producing Cells, and Specific Immunotherapies. Frontiers in Immunology, 2022, 13, 834342.	4.8	14
6	Effects of Teriflunomide on B Cell Subsets in MuSK-Induced Experimental Autoimmune Myasthenia Gravis and Multiple Sclerosis. Immunological Investigations, 2021, 50, 671-684.	2.0	11
7	A Case of HaNDL with Low Cerebrospinal Fluid Level of Neurofilament Light Chain. Case Reports in Neurology, 2021, 12, 334-338.	0.7	3
8	CSF levels of HoxB3 and YKL-40 may predict conversion from clinically isolated syndrome to relapsing remitting multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 48, 102697.	2.0	7
9	Cytokineâ€“chemokine and cognitive profile of multiple sclerosis patients with predominant optic nerve and spinal cord involvement. Journal of Spinal Cord Medicine, 2021, 44, 411-417.	1.4	5
10	Serum anti-ganglioside antibodies in patients with autoimmune limbic encephalitis. Turkish Journal of Medical Sciences, 2021, , .	0.9	1
11	Inflammation and regulatory T cell genes are differentially expressed in peripheral blood mononuclear cells of Parkinsonâ€™s disease patients. Scientific Reports, 2021, 11, 2316.	3.3	20
12	Adaptive immunity cells are differentially distributed in the peripheral blood of glycine receptor antibody-positive patients with focal epilepsy of unknown cause. Epilepsy Research, 2021, 170, 106542.	1.6	4
13	MO678DISTRIBUTION OF PERIPHERAL BLOOD T CELL SUBTYPESÂIN HEMODIALYSIS PATIENTS TREATED WITH MEDIUM CUT-OFF MEMBRANES AND HIGH-FLUXÂMEMBRANES. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0
14	Genetic Association of a Gainâ€ofâ€Function IFNGR1 Polymorphism and the Intergenic Region LNCAROD/DKK1 With BehÃ§etâ€™s Disease. Arthritis and Rheumatology, 2021, 73, 1244-1252.	5.6	21
15	Peripheral blood B cell subset ratios and expression levels of B cell-associated genes are altered in benign multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 52, 103019.	2.0	5
16	Evaluation of Patients with Suspicion of COVID-19 in Pediatric Emergency Department. Sisli Etfal Hastanesi Tip Bulteni, 2021, 55, 179-187.	0.3	2
17	miR-132-3p, miR-106b-5p, and miR-19b-3p Are Associated with Brain-Derived Neurotrophic Factor Production and Clinical Activity in Multiple Sclerosis: A Pilot Study. Genetic Testing and Molecular Biomarkers, 2021, 25, 720-726.	0.7	10
18	The Effect of Cognitive Rehabilitation on Peripheral Blood B Cell Distribution and Specific Gene Expression Levels in MS patients. , 2021, 1, 32-39.		0

#	Article	IF	Citations
19	Sleep disturbance and cognitive decline in multiple sclerosis patients with isolated optic neuritis as the first demyelinating event. International Ophthalmology, 2020, 40, 151-158.	1.4	4
20	Late-onset generalized myasthenia gravis: clinical features, treatment, and outcome. Acta Neurologica Belgica, 2020, 120, 133-140.	1.1	19
21	The treatment effect on peripheral B cell markers in antibody positive myasthenia gravis patients. Journal of Neuroimmunology, 2020, 349, 577402.	2.3	1
22	Expression of Akt1 and p-Akt1 in peripheral T cell subsets of multiple sclerosis patients. Acta Neurologica Belgica, 2020, 121, 1777-1782.	1.1	5
23	Comparison of Circulating Levels of Uremic Toxins in Hemodialysis Patients Treated with Medium Cut-Off Membranes and High-Flux Membranes: Theranova in Sisli Hamidiye Etfal (THE SHE) Randomized Control Study. Blood Purification, 2020, 49, 733-742.	1.8	26
24	Peripheral blood expression levels of inflammasome complex components in two different focal epilepsy syndromes. Journal of Neuroimmunology, 2020, 347, 577343.	2.3	16
25	Common Denominators in the Immunobiology of IgG4 Autoimmune Diseases: What Do Glomerulonephritis, Pemphigus Vulgaris, Myasthenia Gravis, Thrombotic Thrombocytopenic Purpura and Autoimmune Encephalitis Have in Common?. Frontiers in Immunology, 2020, 11, 605214.	4.8	21
26	Expression Levels of Inflammasome Complexes in Experimental Autoimmune Myasthenia Gravis Mouse Model (EAMG). Experimed, 2020, 9, 79-85.	0.1	1
27	Impact of autoimmune demyelinating brain disease sera on pericyte survival. Noropsikiyatri Arsivi, 2020, 58, 83-86.	0.3	3
28	B Cell Immunophenotyping and Expression Analysis of B Cell Specific Molecules of Patients with Benign Multiple Sclerosis. Experimed, 2020, 9, 105-112.	0.1	0
29	Impact of fingolimod on CD4+ T cell subset and cytokine profile of relapsing remitting multiple sclerosis patients. Journal of Neuroimmunology, 2019, 337, 577065.	2.3	9
30	Enhanced NLRP3 and DEFA1B Expression During the Active Stage of Parenchymal Neuro-BehÃ§et's Disease. In Vivo, 2019, 33, 1493-1497.	1.3	8
31	Relation of HLAâ€DRB1 to IgG4 autoantibody and cytokine production in muscleâ€specific tyrosine kinase myasthenia gravis (MuSKâ€MG). Clinical and Experimental Immunology, 2019, 197, 214-221.	2.6	6
32	Serum orexin-A levels are associated with disease progression and motor impairment in multiple sclerosis. Neurological Sciences, 2019, 40, 1067-1070.	1.9	19
33	Acute ophthalmoparesis and persistent mydriasis: expanding the clinical spectrum of anti-gq1b positive cranial neuropathy in a 5.5-year-old girl. Turkish Journal of Pediatrics, 2019, 61, 794.	0.6	2
34	Peripheral blood memory B cell frequency predicts conversion from clinically isolated syndrome to multiple sclerosis. Multiple Sclerosis and Related Disorders, 2018, 23, 9-14.	2.0	8
35	Regulatory B cells in myasthenia gravis are differentially affected by therapies. Annals of Clinical and Translational Neurology, 2018, 5, 1408-1414.	3.7	18
36	Viability of SH-SY5Y cells is associated with purinergic P2 receptor expression alterations. Acta Biologica Hungarica, 2017, 68, 22-34.	0.7	0

#	Article	IF	Citations
37	Immunization with Recombinantly Expressed LRP4 Induces Experimental Autoimmune Myasthenia Gravis in C57BL/6 Mice. Immunological Investigations, 2017, 46, 490-499.	2.0	19
38	Prompt Response to Prednisone Predicts Benign Course in MuSK-MG. European Neurology, 2017, 78, 137-142.	1.4	5
39	Flow Cytometry Analysis of Peripheral Blood B Cell Distribution of Patients with Multiple Sclerosis. Turk Noroloji Dergisi = Turkish Journal of Neurology, 2017, 23, 219-224.	0.3	1
40	Genetic heterogeneity within the HLA region in three distinct clinical subgroups of myasthenia gravis. Clinical Immunology, 2016, 166-167, 81-88.	3.2	38
41	Chemokine and Chemokine Receptor Polymorphisms in Bipolar Disorder. Psychiatry Investigation, 2016, 13, 541.	1.6	7
42	Activation of the JAK/STAT pathway in Behcetâ€™s disease. Genes and Immunity, 2015, 16, 170-175.	4.1	59
43	cFLIP overexpression in T cells in thymomaâ€associated myasthenia gravis. Annals of Clinical and Translational Neurology, 2015, 2, 894-905.	3.7	3
44	B cells produce less IL-10, IL-6 and TNF-Î±in myasthenia gravis. Autoimmunity, 2015, 48, 201-207.	2.6	26
45	Differential Cytokine Changes in Patients with Myasthenia Gravis with Antibodies against AChR and MuSK. PLoS ONE, 2015, 10, e0123546.	2.5	40
46	Preferential production of IgG1, IL-4 and IL-10 in MuSK-immunized mice. Clinical Immunology, 2014, 151, 155-163.	3.2	35
47	Prepubertal anti-Musk positive myasthenia gravis with long remission. Neuromuscular Disorders, 2014, 24, 36-39.	0.6	6
48	Differential cytokine changes in myasthenia gravis patients with antibodies against AChR and Musk. Journal of Neuroimmunology, 2014, 275, 212-213.	2.3	0
49	The Association of PTPN22 R620W Polymorphism Is Stronger with Late-Onset AChR-Myasthenia Gravis in Turkey. PLoS ONE, 2014, 9, e104760.	2.5	10
50	Association of HLA-DRB1âˆ—14, -DRB1âˆ—16 and -DQB1âˆ—05 with MuSK-myasthenia gravis in patients from Turkey. Human Immunology, 2013, 74, 1633-1635.	2.4	43
51	Aquaporinâ€4 antibody seropositivity in myasthenia gravis patients with thymoma. Muscle and Nerve, 2013, 47, 306-307.	2.2	0
52	Identification of multiple independent susceptibility loci in the HLA region in BehÃ§et's disease. Nature Genetics, 2013, 45, 319-324.	21.4	130
53	Takayasu's arteritis is associated with HLA-B*52, but not with HLA-B*51, in Turkey. Arthritis Research and Therapy, 2012, 14, R27.	3.5	60
54	A putative functional variant within the UBAC2 gene is associated with increased risk of BehÃ§et's disease. Arthritis and Rheumatism, 2011, 63, 3607-3612.	6.7	39

#	Article	IF	Citations
55	Increased Complement Consumption in MuSK-Antibody-Positive Myasthenia Gravis Patients. Medical Principles and Practice, 2011, 20, 581-583.	2.4	9
56	Mannose-binding lectin pathway is not involved in myasthenia gravis pathogenesis. Journal of Neuroimmunology, 2009, 208, 40-45.	2.3	7
57	Long Remission in Muscle-Specific Kinase Antibody-Positive Juvenile Myasthenia. Pediatric Neurology, 2009, 40, 455-456.	2.1	22
58	Polymorphisms of interferon-Î³, interleukin-10, and interleukin-12 genes in myasthenia gravis. Human Immunology, 2007, 68, 544-549.	2.4	17
59	Interleukin (IL)-12, IL-2, interferon-Î³ gene polymorphisms in subacute sclerosing panencephalitis patients. Journal of NeuroVirology, 2007, 13, 410-415.	2.1	27
60	Interleukin (IL)â€“12, IL-2, and IL-6 Gene Polymorphisms in Takayasuâ€™s Arteritis from Turkey. Human Immunology, 2006, 67, 735-740.	2.4	47
61	IL-12 and IL-10 polymorphisms and their effects on cytokine production. Cytokine, 2005, 30, 188-194.	3.2	144
62	Polymorphisms of the IL-8 and CXCR2 genes are not associated with BehÃ§et's disease. Journal of Rheumatology, 2005, 32, 93-7.	2.0	13
63	Impact of IntraventrÃcular Administration of SWAP-70 Antibody Positive Multiple Sclerosis Serum Antibodies on Motor Activity and Brain Histology. Experimed, 0, , .	0.0	0